Article · Volume 2, Issue 1 · pp. 28–35
A prospective study comparing Total Lymphocyte Count (TLC) and CD4 counts in HIV patients in a resource limited setting in India
Lincy Lal1, Cijo George2, Anitha Yesoda3, Jayakumar B4
- 1Pharmcoeconomic Research Specialist, Drug Use Policy and Pharmacoeconomics, UT MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 706, Houston, Texas 77030.
- 2Manager-Clinical Pharmacy, HCG Towers, P.Kalinga Rao Road, Bangalore-27, Karnataka, INDIA.
- 3Asso. Professor, College of Pharmaceutical sciences, Medical college, Thiruvananthapuram, Kerala, INDIA.
- 4Prof & Head, Dept. Of Medicine, Medical college Hospital, Thiruvananthapuram, Kerala, INDIA.
Abstract
Even after 25 years of the first detection of Acquired Immunodeficiency Syndrome (AIDS), it remains a major health care problem without any cure. Extensive research around the world and the subsequent introduction of highly active antiretroviral therapy (HAART) has produced dramatic reduction on morbidity, mortality and health care utilization. HAART regimens have revolutionized the treatment of human immunodeficiency virus (HIV), which consistently results in sustained suppression of HIV-1 RNA replication, resulting in gradual increases in CD4 T lymphocyte count, sometimes to normal levels.
The full text of this article is available as a PDF. Open the PDF.